Synchron

Synchron: Undisclosed valuation, IPO Readiness 51, Series D. Developing the Stentrode — the world's only brain-computer interface that requires no open-brain surgery, enab. Track live on The IPO Stack.

Series DMedical Technologyprivate
51
/100
IPO Readiness Score
Grade D — Early Stage
TechStackIPO proprietary score based on funding scale, valuation, stage progression & momentum.
Track Synchron →

Developing the Stentrode — the world's only brain-computer interface that requires no open-brain surgery, enabling people with severe paralysis to control digital devices with their thoughts.

Valuation
Undisclosed
Total Funding
$345M
Stage
Series D
Sector
Medical Technology
Headquarters
New York, NY
CEO
Tom Oxley
IPO Status
private

Funding History

Round Amount Date Lead Investors
Series D $200M Nov 2025 Double Point Ventures
Series C $75M Dec 2022 ARCH Venture Partners
Series B $52M Jun 2021 ARCH Venture Partners
Series A $10M Apr 2017 Private Investors
The IPO Stack Newsletter

Get Tuesday's IPO moves + one deep-dive in your inbox

Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.

🚀

2026 IPO Watchlist

Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.

SpaceX
$1.75T · Aerospace & Defense
95
Readiness
SpaceX
$1.75T · Aerospace & Defense
95
Readiness
Anthropic
$380B · Artificial Intelligence
94
Readiness
Cerebras Systems
$23.1B · Semiconductors
94
Readiness
OpenAI
$852B · Artificial Intelligence
93
Readiness
Anthropic
$380B · Artificial Intelligence
91
Readiness
Databricks
$134B · Enterprise Software
90
Readiness
OpenAI
$852B · Artificial Intelligence
90
Readiness

Track Synchron IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.

Loading company data...

Frequently Asked Questions

When is Synchron going public? +

Synchron has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.

What is Synchron's current valuation? +

Synchron is valued at Undisclosed as of the most recent funding round. This valuation is based on its most recent private funding round tracked by TechStackIPO.

How can I invest in Synchron before IPO? +

Accredited investors can access Synchron shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.

What is Synchron's IPO Readiness Score? +

Synchron scores 51/100 (Grade: D) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.

How much total funding has Synchron raised? +

Synchron has raised $345M in total venture capital and private equity funding, with backing from Double Point Ventures, ARCH Venture Partners, Private Investors.

Who are Synchron's key investors? +

Synchron's notable investors include Double Point Ventures, ARCH Venture Partners, Private Investors. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.

What sector is Synchron in? +

Synchron is a Medical Technology company. Developing the Stentrode — the world's only brain-computer interface that requires no open-brain surgery, enabling peopl.